Post-patent drugs usually have insane prices due to reasons outside of what can be effectively combatted by the bargaining power of universal healthcare (e.g. regulatory capture in the case of EpiPen). That tactic is rarely necessary once generics enter the mix, as long as nothing is artificially preventing them from getting to market.